- Home
- FORA vs KPTI Comparison
FORA vs KPTI Comparison
Compare FORA & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- KPTI
- Stock Information
- Founded
- FORA 2014
- KPTI 2008
- Country
- FORA United States
- KPTI United States
- Employees
- FORA N/A
- KPTI N/A
- Industry
- FORA Computer Software: Prepackaged Software
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- KPTI Health Care
- Exchange
- FORA Nasdaq
- KPTI Nasdaq
- Market Cap
- FORA 77.6M
- KPTI 81.1M
- IPO Year
- FORA N/A
- KPTI 2013
- Fundamental
- Price
- FORA $2.41
- KPTI $0.60
- Analyst Decision
- FORA Strong Buy
- KPTI Strong Buy
- Analyst Count
- FORA 1
- KPTI 4
- Target Price
- FORA $5.00
- KPTI $5.00
- AVG Volume (30 Days)
- FORA 57.0K
- KPTI 840.0K
- Earning Date
- FORA 03-27-2025
- KPTI 02-19-2025
- Dividend Yield
- FORA N/A
- KPTI N/A
- EPS Growth
- FORA N/A
- KPTI N/A
- EPS
- FORA N/A
- KPTI N/A
- Revenue
- FORA $19,709,723.00
- KPTI $145,237,000.00
- Revenue This Year
- FORA N/A
- KPTI $4.47
- Revenue Next Year
- FORA $13.59
- KPTI $7.35
- P/E Ratio
- FORA N/A
- KPTI N/A
- Revenue Growth
- FORA N/A
- KPTI N/A
- 52 Week Low
- FORA $1.96
- KPTI $0.53
- 52 Week High
- FORA $4.15
- KPTI $1.70
- Technical
- Relative Strength Index (RSI)
- FORA 48.34
- KPTI 41.56
- Support Level
- FORA $2.35
- KPTI $0.53
- Resistance Level
- FORA $4.03
- KPTI $0.64
- Average True Range (ATR)
- FORA 0.45
- KPTI 0.05
- MACD
- FORA -0.01
- KPTI -0.00
- Stochastic Oscillator
- FORA 19.00
- KPTI 44.13
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.